Updated: Roche predicts its breast cancer pill could become its biggest-selling drug
更新：罗氏预测其乳腺癌口服药或将成为公司最畅销药物

With two positive clinical readouts in the bag, a US approval filing, and another important trial due to report in a couple months, Roche’s breast cancer drug giredestrant is sitting pretty.
在拿下两项临床阳性读出、已向美国提交上市申请、且另一项重要试验将于数月内出结果的背景下，罗氏的乳腺癌药物giredestrant形势大好。